Aspen RxHealth

aspenrxhealth.com →

-83%

est. 2Y upside i

HealthcareSeries B

Rank

#4246

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Low

The equity opportunity for Aspen RxHealth is highly risky due to its acquisition by MedImpact HealthCare Systems, a private company with limited liquidity for employee equity.

Last updated: March 10, 2026

Bull (15%)+100%

Aspen RxHealth's platform and pharmacist network are successfully integrated into MedImpact, driving significant new revenue streams and operational efficiencies for the parent company. This leads to a strong performance for MedImpact, potentially doubling the implied value of Aspen RxHealth's contribution to approximately $945M within MedImpact's private valuation, leading to enhanced internal equity value or a future, more favorable liquidity event for MedImpact.

Base (25%)0%

Aspen RxHealth's integration into MedImpact proceeds with moderate success, contributing steadily to MedImpact's existing PBM services. However, MedImpact faces ongoing competitive and regulatory pressures, and the recent layoffs temper overall growth. The implied value of Aspen RxHealth's contribution to MedImpact remains stable at approximately $472M, with no significant appreciation for new equity holders over the 2-year horizon.

Bear (60%)-70%

Integration challenges, combined with MedImpact's recent layoffs and intense competition in the PBM market, hinder Aspen RxHealth's ability to drive significant value. The parent company's performance is negatively impacted, leading to a substantial write-down of Aspen RxHealth's internal value or a lack of value creation for MedImpact equity, resulting in a 70% decrease in the implied value of Aspen RxHealth's contribution to approximately $142M.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Based on Aspen RxHealth's last known total funding of $32M and a hypothetical implied valuation of ~$472M, the funding intensity is approximately 6.8%, which is moderate. However, this is less relevant for new equity grants post-acquisition, as the preference stack would be at the MedImpact level.

Dilution Risk

high

As a private company, MedImpact's future funding rounds or internal equity grants could lead to further dilution, which is difficult for employees to track or influence.

Secondary Liquidity

none

There is no active secondary market for equity in a private company like MedImpact, severely limiting an employee's ability to sell shares.

View all 7 open roles at Aspen RxHealth →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Aspen RxHealth's data — designed to show you've done your homework.

  • 1

    “Given Aspen RxHealth's acquisition by MedImpact, how is the company thinking about the integration strategy, particularly in light of the recent layoffs at MedImpact, and what specific synergies are being prioritized?”

  • 2

    “With Aspen RxHealth's focus on clinical pharmacy services and MedImpact's PBM operations, how does the combined entity plan to differentiate itself and compete against the 'Big Three' PBMs (CVS Caremark, Express Scripts, OptumRx) amidst increasing regulatory scrutiny?”

  • 3

    “Considering MedImpact is a private company, what are the realistic liquidity pathways for employee equity (RSUs/options) over a 2-5 year horizon, and what mechanisms are in place for employees to understand and realize the value of their equity?”

Community

Valuation Sentiment

Our model estimates -83% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.